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Abstract
Background/Aim—Certain host genetic polymorphisms reportedly affect the likelihood of a
sustained virological response (SVR) to interferon treatment in subjects infected with hepatitis C
virus (HCV). As part of the HALT-C trial we evaluated genetic associations among patients
infected with HCV genotype 1 who had failed previous interferon treatment.
Methods—SVR was determined 24 weeks after completing treatment with pegylated interferon
alfa-2a and ribavirin. Eight single nucleotide polymorphisms (SNPs) were selected on the basis of
previously reported associations with treatment response. Genotypes were assessed by polymerase
chain reaction-based assays. The percentage of patients who achieved SVR was determined for
each genotype and for an IL-10 promoter diplotype.
Results—Among 637 non-Hispanic Caucasian patients there were no significant associations
between genotype for any individual SNP (IL10 -1082, IL10 -592, TNF -308, TNF -238, TGFB1
codon 25, CCL2 -2518, EPHX1 codon 113 and AGT -6) and SVR, but SVR was more common
among the patients who were homozygous for the ACC IL-10 promoter diplotype (adjusted odds
ratio, 3.24; 95% confidence interval, 1.33–7.78; p=0.001).
Conclusions—Among non-Hispanic Caucasian patients treated with peginterferon and ribavirin
after failing previous treatment with interferon, homozygosity for the ACC IL-10 promoter
diplotype was associated with SVR.
Keywords
hepatitis C; chronic/genetics; polymorphism; genetic; interferon-alpha/therapeutic use; gene
frequency
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Sequencing of the human genome has brought the promise of individualized medicine.
Inheritable genetic factors influence the risk of development or clinical course of a variety of
diseases(1–3), and may affect response to drug treatment (4–6). In the case of chronic
hepatitis C, recent papers have suggested that a number of genetic polymorphisms may
influence the outcome of chronic hepatitis C infection or a patient’s response to antiviral
therapy (7–16).
The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial is an NIH-
sponsored clinical trial designed to improve the management and outcomes for patients with
difficult-to-cure, advanced chronic hepatitis C. As part of an ancillary study of the HALT-C
trial, we carried out genetic testing of a series of candidate genetic variations which had
been reported to be associated with either response to interferon-based therapy (7–16) or
with risk of developing hepatic fibrosis (17–20), which is itself a predictor of therapeutic
response. Studying these genetic variations in the HALT-C trial presents an opportunity to
assess whether previously-reported host genetic factors predict response to treatment with




The over-all design of the HALT-C trial, along with the major clinical, biochemical, and
virological responses to the ‘Lead-in’ phase of therapy have been published (21, 22). In
brief, patients with advanced chronic hepatitis C (Ishak fibrosis score >2) (23) who had not
previously responded to interferon treatment (either with or without ribavirin) and who had a
Child-Turcotte-Pugh score <7 were invited to enroll.
Treatment during the Lead-in phase (i.e., first 24 weeks) consisted of pegylated interferon
alfa-2a (Pegasys®) 180 mcg/week subcutaneously, plus ribavirin (Copegus®) 1.0–1.2 g
orally per day. Subjects with undetectable HCV RNA at week 20 were offered 48 weeks of
treatment with pegylated interferon and ribavirin, and were followed for another 24 weeks
after treatment was stopped. Subjects were considered to have a sustained virologic response
(SVR) if they had undetectable HCV RNA 24 weeks after discontinuing pegylated
interferon and ribavirin treatment.
All subjects had a liver biopsy performed within 12 months prior to entry into the HALT-C
trial which was scored for fibrosis using the Ishak fibrosis scale (range 0 through 6) by a
group of hepatopathologists Steatosis was scored as not present (0), less than 5% of
hepatocytes (1), 5–33% of hepatocytes (2), 33–66% (3) or greater than 66% (4). An
estimated duration of hepatitis C infection was determined by the study principal
investigator. Race was self-classified as White, Black, Asian/Pacific Islander, American
Indian/Alaskan Native, other or unknown. Ethnicity was recorded as Latino/Hispanic or not.
Subjects who considered themselves as White but not Latino/Hispanic were classified as
non-Hispanic Caucasians and those who self-categorized as Black were classified as African
American.
Genetic Ancillary Study
All subjects entering the HALT-C trial were offered participation in an ancillary study to
evaluate genetic polymorphisms associated with hepatitis C disease severity and response to
treatment. Of the 1145 subjects enrolled in the Lead-in phase of the HALT-C trial, 1051
(91.7%) agreed to participate in the genetics study (Fig 1). Since genetic polymorphisms can
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vary by race/ethnicity, we analyzed data from non-Hispanic Caucasians and African
Americans separately. Because only 9 African Americans participants achieved an SVR, a
priori statistical power was low in this group. Other groups (e.g., Hispanics, Asians, other)
were present in too few numbers to permit any meaningful statistical analysis and were,
therefore, excluded from this analysis.
The analysis of SVR was further limited to patients with HCV genotype 1 infection who
were enrolled in the Lead-in phase of the HALT-C trial and who completed follow-up
through week 72 (n=774). Patients with other HCV genotypes were excluded because of
different SVR rates among genotype 1 and non-1 subjects in the HALT-C trial (22). Because
severity of liver fibrosis may affect SVR (22), we also evaluated the association of selected
SNPs with liver fibrosis, measured both as Ishak fibrosis score at entry into the trial and as a
fibrosis rate, which was determined by dividing the Ishak fibrosis score by the estimated
number of years of infection.
DNA Extraction and Genotyping
DNA was extracted at SeraCare (Gaithersburg, MD) from frozen whole blood using the
Gentra Systems Puregene kit (n=117) and from either Epstein-Barr transformed B-
lymphocytes (n=636) or frozen peripheral blood mononuclear cells (n=21) using Qiagen
DNA purification columns (Qiagen Inc, Valencia, CA). Most patients (62.4%) who achieved
SVR had DNA extracted by the Gentra Systems method, whereas 96.8% of patients who did
not achieve SVR had DNA extracted by the Qiagen method. Eight single nucleotide
polymorphisms (SNPs) from six genes (IL10 -1082 A/G; IL10 -592 A/C; TNF -308 A/G;
TNF -238 A/G; TGFB1 codon 25 R/P [Arg/Pro]; CCL2 -2518 G/A; EPHX1 codon 113 Y/H
[Tyr/His]; AGT -6 A/G) were measured by polymerase chain reaction-based assays
performed at the University of Connecticut Health Center. Details of these assays are shown
in Supplemental Table 1.
Data Analysis
All data were analyzed by the New England Research Institutes Data Coordinating Center
using SAS (Statistical Analysis Software, version 9.1, SAS Institute, Cary, NC, USA). All
analyses were stratified by race. For each SNP, we used Pearson’s Chi-sq to compare
observed genotype proportions to those expected under Hardy-Weinberg equilibrium. For
each genotype, we determined the proportion of patients who achieved SVR. The odds ratio
(OR) and corresponding 95% confidence interval (CI) were computed using logistic
regression models. We considered as potential covariates factors previously shown to be
associated with SVR among HALT-C subjects (i.e., prior treatment with interferon
monotherapy, cirrhosis, pretreatment HCV RNA level, HFE H63D genotype) (22, 24) or
other populations (e.g., age, gender, BMI, steatosis, etc) (25, 26). Our final models included
five variables that were independently associated with SVR among our patients (pre-
treatment HCV RNA level, presence of cirrhosis, AST/ALT ratio, baseline viral load, HFE
H63D genotype, and whether the patient had received ribavirin prior to entering the HALT-
C trial).
IL10 (-1082/-819/-592) promoter haplotypes were determined based on genotype results for
IL10 -1082 (A/G) and IL10 -592 (C/A) as well as the previously reported linkage between
IL10 -819 (T/C) and IL10 -592 (C/A) (10). The three observed IL10 promoter haplotypes are
GCC, ACC or ATA. We determined the proportion of patients who achieved SVR by IL10
promoter diplotype, along with the OR and 95% CI. ‘Statistical significance’ was based on
p<0.05. To evaluate the association of host genotype with fibrosis progression rate and Ishak
fibrosis score, t-tests were used to compare mean differences between genotypes.
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Characteristics of Subjects Studied
Selected demographic and clinical information is summarized in Table 1. The 1051 genetic
study participants did not differ from the overall group of participants in any meaningful
way. Because the current analysis was restricted to subjects who were infected with HCV
genotype 1 and who reported their race as Caucasian, non-Hispanic or African American,
subjects in our report differ from the overall HALT-C participants with regard to those
variables. Among subjects included in the present analysis, the SVR rate was 16% among
non-Hispanic Caucasians and 7% among African Americans. Data from African American
subjects is made available for potential meta-analyses in supplemental tables 2 and 3.
Genetic Polymorphisms and Sustained Virological Response
Host genotype was successfully obtained for each of the eight SNPs from all specimens
tested (Table 2). For all 8 alleles examined, the distribution of genotypes was consistent with
the proportions expected under Hardy-Weinberg equilibrium. Among non-Hispanic
Caucasians, SVR was somewhat less common among carriers of the IL10 -1082 G (OR,
0.87) or the IL10 -592 A (OR, 0.78) polymorphisms, but neither difference was statistically
significant (Table 2). Analysis of four polymorphisms in three additional cytokine genes
(TNF -308 A/G promoter, TNF -238 A/G promoter, TGFB1 codon 25 R/P and CCL2 -2518
G/A promoter) also failed to show an association between genotype and SVR rate among
non-Hispanic Caucasians, as did our analysis for the variant that alters EPHX1 codon 113.
For the AGT -6 A/G promoter genotype, the adjusted analysis yielded an OR of 0.62 (95%
CI, 0.38–1.01; p=0.05). Because the AGT -6 promoter was previously associated with
fibrosis, we repeated the multivariate analysis excluding variables correlated with cirrhosis
(i.e., histological cirrhosis and AST/ALT ratio). In this model the association of AGT -6 with
SVR was slightly less (OR=0.69; 95% CI 0.44 – 1.11; p=0.13).
IL10 Promoter Haplotypes and Sustained Virological Response
Among non-Hispanic Caucasians, the GCC haplotype was more frequent (48.7%) than ACC
(26.8%) or ATA (24.5%) (Table 3). The frequency of SVR was highest (32%) among
patients who were homozygous for the ACC haplotype (who comprised 5.8% [37/637] of
our study population) and there was a significant difference when ACC homozygotes were
compared to GCC homozygotes (OR, 2.59; 95% CI, 1.14 5.87; p=0.02). SVR was not more
common among those who were heterozygous for ACC. Patients who were homozygous for
the ATA haplotype had the lowest rate of SVR (8%), but this difference was not statistically
significant. In a logistic regression model that controlled for pre-treatment HCV RNA level,
presence of cirrhosis, prior treatment with ribavirin, AST/ALT ratio and HFE H63D
genotype (all of which were independently associated with SVR) (22, 24), the association
with the ACC/ACC diplotype became stronger (adjusted OR 3.24; CI: 1.33 – 7.78;
p=0.001), but results for other diplotypes did not change meaningfully (Table 3). Patients
with the ACC/ACC IL10 diplotype also had the greatest decline in HCV RNA at week 12
(2.66 log10 IU/mL vs. approximately 2.3 log10 for the other diplotypes) and the highest
frequency of end-of-treatment response (43% of subjects had undetectable HCV RNA; OR:
1.62, 95% CI: 0.78 – 3.39). However, neither finding reached statistical significance.
Genetic Polymorphisms and Fibrosis
Because advanced fibrosis has been associated with several of the SNPs that we studied
(17– 20, 27) and with reduced response to antiviral therapy (22), fibrosis stage was a
potential confounder in our analysis of response to interferon therapy. We examined host
genotype results for their relationship to mean Ishak fibrosis score and fibrosis progression
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rate among all subjects for whom these data were available (fibrosis score, n=1128; fibrosis
rate, n=1063) as well as in the 774 subjects participating in the SVR analysis. No significant
associations were observed in either racial group for any of the eight SNPs (data not shown).
Discussion
This study examined whether genetic variants that had previously been associated with
either response to interferon treatment or liver fibrosis predicted response to treatment with
pegylated interferon alfa-2a plus ribavirin in a large study of subjects from the United States
with advanced chronic hepatitis C who had failed a previous course of interferon-based
treatment. Although neither the IL10 -1082 nor the IL10 -592 promoter polymorphism alone
predicted response to treatment, the IL-10 ACC/ACC diplotype was associated with SVR
and this association was relatively strong, especially after adjustment for other predictors of
SVR. We also note that the frequency of ACC/ACC diplotype among the HALT-C
population (5.8%) was lower than that observed in the general adult population by Trompet
(7.3%), Gowans (7.8%) and Klein (10%) (28–30) suggesting that subjects with this
diplotype were underrepresented in the HALT-C cohort, perhaps because HCV-infected
subjects with this diplotype responded well to initial treatment with interferon. Some studies
of IL10 ACC function suggest that this haplotype (and the IL10 ATA haplotype) produces
less IL-10 than the GCC haplotype (10, 31), although another study failed to confirm that
finding (32). Nelson and colleagues reported that administration of IL-10 resulted in an
increase in HCV RNA level and a flare of ALT (33). A possible explanation for the
observed association is that persons who are homozygous for IL10 ACC produce less IL-10
which leads to improved control of HCV.
Results from previous studies of the IL10 haplotype and response to interferon based
treatment for chronic hepatitis C are inconsistent. Among patients who received interferon
monotherapy, Edwards-Smith reported higher SVR rates among patients carrying ACC than
the GCC haplotype (10), and the highest SVR rates among patients carrying the also
putatively low producing ATA haplotype. Therefore, the results from that study are
consistent with the hypothesis that haplotypes associated with low IL-10 production might
increase the likelihood of SVR. In apparent conflict, however, is a study by Knapp who
reported that patients homozygous for GCC, who might be expected to have the highest
production of IL-10, were more likely to achieve SVR (11). Yee et al. (15) reported IL10
haplotype results that are not directly comparable to other studies because they included
additional genetic variants in extended IL10 haplotypes. One of the two extended IL10
haplotypes that included ATA was associated with SVR and one of the two extended IL10
haplotypes that included ACC had the opposite association. Finally, Mangia et al. (12) found
no statistically significant associations between any IL10 haplotype and response to
treatment, but that study had low statistical power because it was limited to 95 patients.
Taken as a whole, the data fail to provide a consistent picture of the relationship between
IL10 haplotypes and response to treatment for HCV.
Prior studies of individual IL10 promoter polymorphisms are also inconsistent. Edwards-
Smith found that carriage of the IL10 -592A allele was associated with viral clearance
during the first 12 weeks of treatment (OR=5.1; 95% CI 1.4–19.1) (10) and Yee found an
association between the -592A allele and SVR(15),. Knapp found no association of IL10
-592A and SVR but reported that the -1082 GG genotype was associated with SVR
(OR=2.28; p=0.005), and, somewhat paradoxically, that the -1082 AG heterozygous
genotype had the opposite association (11). Three additional reports (two from Europe and
one from the United States) found no association between either the -592A allele or the
-1082G allele and SVR (8, 12, 14).
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The reason for the different results reported from studies of the association of IL10 promoter
variants and virologic response is not clear. The study populations differ with regard to
factors that are related to response to interferon-based treatments such as the degree of liver
fibrosis, exclusion of HCV non-1 genotypes or type of interferon used (pegylated vs.
regular). Furthermore, environmental factors including lower body mass index, smoking and
female gender, which have been linked to decreased IL-10 production (34), may vary
between studies. It is also possible that the observed differences between studies, including
our finding that the ACC/ACC diplotype is associated with SVR, could be due to chance.
We were motivated to study TNF promoter polymorphisms because Dai et al. reported that
Taiwanese patients receiving peginterferon and ribavirin were more likely to achieve SVR if
they carried TNF -308 A (9). However neither the TNF -238 nor TNF -308 TNF was
associated with SVR in our analysis. Other studies from the United States (15, 19), Europe
(2, 7, 8, 13) and Taiwan (16) also failed to detect an association of either TNF promoter
polymorphism with viral clearance following interferon treatment. Furthermore, recent
studies have cast doubt on the functional significance of the -238 and the -308
polymorphisms (35). Taken together, the cumulative evidence does not indicate that TNF
promoter genotype alters response to interferon treatment of chronic HCV.
Because fibrosis is associated with an increased risk of failure of interferon treatment, we
also examined polymorphisms that have been associated with an increased risk of fibrosis
but have not been assessed for their relationship to SVR (18, 19). We were unable to
demonstrate an association of the TGFB1 codon 25 allele and response to treatment,
confirming one prior negative study (14). Alleles at -2518 of the CCL2 promoter region
were not associated with SVR in either Caucasians or in African Americans, which is in
agreement with two prior reports (36, 37). We found no association between EPHX1 Y113H
polymorphism and SVR, but the data suggested that the AGT -6 GG genotype might be
associated with increased response to treatment. Further study of this polymorphism is
warranted.
The fact that HALT-C trial participants have advanced fibrosis and are non-responders to
prior treatment with interferon raises the question of whether our results can be compared
with other studies of patients with chronic hepatitis C. Restriction of enrollment to previous
non-responders likely eliminates patients who are most responsive to interferon, but it also
enriches for patients who are truly non-responsive to treatment with interferon. It is
plausible that epidemiologic associations for treatment response to pegylated interferon plus
ribavirin could be weaker among patients who previously failed interferon therapy, but the
available data do not support this concern. HALT-C investigators have replicated the
reported risk factors for treatment failure (i.e., older age, African American ethnicity, HCV
genotype 1, higher HCV RNA level, the presence of cirrhosis) that were found in trials of
previously untreated patients (26, 38– 40) and these associations were at least as strong
among the HALT-C participants (22).
Enrollment into HALT-C was limited to subjects with bridging fibrosis or cirrhosis (i.e.,
Ishak fibrosis score of 3 through 6). The exclusion of subjects with minimal fibrosis restricts
our ability to examine the relationship between genetic polymorphism and liver fibrosis.
Furthermore, because of the lack of data demonstrating that risk factors for fibrosis are
similar in HALT-C subjects and in subjects in published trials evaluating SNPs and liver
fibrosis, we did not report data on host SNPs and liver fibrosis. None-the-less, we did
evaluate association of SNPs and liver fibrosis score and fibrosis rate because of the
potential for these SNPs to influence liver fibrosis and thereby confound their effect on
SVR. Our failure to demonstrate an association of host SNPs with liver fibrosis makes it
unlikely that the SNPs we evaluated affected SVR by influencing liver fibrosis.
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We believe that our study represents the largest analysis to date of host genetics and
response to treatment for chronic hepatitis C. The statistical power to detect a two-fold
association between presence of an allele and SVR ranged from 87–94% for the alleles that
we studied with the exception of TNF -238 (45%) and TGFB1 -25 (70%), but the power to
find a 1.5 fold association with SVR was low for all genotypes. Other strengths of our study
include uniform treatment of patients with the current ‘gold standard’ regimen (pegylated
interferon plus ribavirin) and careful follow-up for treatment outcomes within the context of
an NIH-sponsored clinical trial.
In summary, among non-Hispanic Caucasians infected with genotype 1 hepatitis C virus and
moderate-to-advanced liver fibrosis, SVR was more common among participants who were
homozygous for the ACC IL10 diplotype, which has been linked to low production of IL10.
We could not confirm a number of prior associations of DNA polymorphisms with sustained
virological response to interferon treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Overview of patients participating in the Lead-in phase of the HALT-C trial who agreed to
participate in the genetics study and who were included in the current report.
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Table 1
Selected demographic and clinical features of subjects participating in the Lead-in phase of the HALT-C trial,
the genetics ancillary study, and in the current report










Age (mean, sd) 50 (7.30) 50 (7.24) 50.1 (7.04)
Male (n, %) 827 (72%) 760 (72%) 563 (73%)
Race
  Caucasian, non-Hispanic (n,%) 844 (74%) 783 (75%) 637 (82%)
African American (n, %) 175 (15%) 154 (15%) 137 (18%)
Other (n, %) 126 (11%) 114 (11%) 0 (0%)
Estimated years of infection (mean, sd) 28.11 (8.13) 28.27 (8.13) 27.95 (7.77)
BMI (mean, sd) 29.7(5.4) 29.7(5.5) 29.7(5.5)
Ishak Fibrosis Score
2–4 (n, %) 713 (62%) 653 (62%) 488 (63%)
5–6 (n, %) 430 (38%) 396 (38%) 286 (37%)
Ishak Inflammation Score (mean, sd) 7.5 (2.1) 7.5 (2.1) 7.30 (2.0)
Steatosis score
0 or 1 694 (61%) 637 (61%) 477 (62%)
2 348 (30%) 321 (31%) 228 (30%)
3 88 (8%) 80 (8%) 59 (8%)
4 15 (1%) 13 (1%) 10 (1%)
AST/ALT ratio (mean, sd) 0.84 (0.29) 0.82 (0.29) 0.85 (0.29)
HCV Genotype 1 (n, %) 1017 (89%) 929 (89%) 774 (100%)
HCV RNA level < 1.5 million IU/mL (n,%) 323 (28%) 302(29%) 207(27%)
HCV RNA level (log 10) (mean, sd) 6.42 (0.53) 6.41 (0.54) 6.44 (0.53)
Prior treatment:
Interferon alone (n, %) 326 (28%) 298 (28%) 205 (26%)
Interferon and ribavirin (n, %) 819 (72%) 753 (72%) 569 (74%)
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*Subjects enrolled in Lead-in phase, infected with HCV genotype 1 who reported race as Caucasian, non-Hispanic or as African American and
who had HCV RNA results available at Week 20 and at Week 72. Because the current analysis was restricted to non-Hispanic Caucasians and
African Americans who were infected with HCV genotype 1, these groups differ from the overall HALT-C participants (p<0.05).
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